Biomea Fusion said enrollment continues in its Phase II COVALENT-211 trial of icovamenib for insulin-deficient type 2 diabetes, signaling progress in its metabo

Biomea Fusion said enrollment continues in its Phase II COVALENT-211 trial of icovamenib for insulin-deficient type 2 diabetes, signaling progress in its metabolic disease pipeline. Earlier Phase II data also showed durable HbA1c improvement.